TUCSON, Ariz., – April 11, 2022 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company, today announced a publication in the peer-reviewed scientific journal, Nature Scientific Reports, outlining a novel technique in cardiac magnetic resonance imaging (CMR) data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences, entitled, “Free-breathing gradient recalled echo-based CMR in a swine heart failure model,” (Morris, el al. (2022). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07611-8). [Read more…]
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies
April 8th, 2022, Kobe, Japan – TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). [Read more…]
PeptiGrowth Inc. is launching a novel synthetic TrkB agonist peptide (BDNF alternative)
April 4, 2022, Tokyo, Japan — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel TrkB agonist peptide which has the equivalent functions to recombinant Brain Derived Neurotropic Factor (BDNF). We will be marketing this product (BDNF alternative) from the beginning of April, 2022. [Read more…]
A Timeline of Landmark Events in the Stem Cell Industry
Research and experimentation have been driving progress within the stem cell industry for decades. Despite major advances in stem cell knowledge, current medical approaches still rely heavily on pharmaceuticals and a surgeon’s scalpel. There is irony in the term “modern” medicine, because its central focus has largely been to address symptoms and not underlying medical issues. “Diabetic? No problem, we can regulate your insulin.”
Under our current framework for medicine, regenerative medicine has not played a central role.
[Read more…]
StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product
StemCyte, a regenerative cell therapy company, has applied to the U.S. FDA for a BLA for its allogeneic umbilical cord hematopoietic progenitor cell product (HPC-Cord Blood)
StemCyte’s BLA has been accepted for quality review and StemCyte anticipates licensure in 2023
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 336
- Next Page »